



(12) Translation of
European patent specification

(11) NO/EP 3052476 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 213/81 (2006.01)
A61K 31/166 (2006.01)
A61K 31/415 (2006.01)
A61K 31/4155 (2006.01)
A61K 31/421 (2006.01)
A61K 31/426 (2006.01)
A61K 31/4418 (2006.01)
A61K 31/4427 (2006.01)
A61K 31/4468 (2006.01)
A61K 31/505 (2006.01)
A61P 35/00 (2006.01)
C07C 233/65 (2006.01)
C07D 213/84 (2006.01)
C07D 231/36 (2006.01)
C07D 239/47 (2006.01)
C07D 263/34 (2006.01)
C07D 277/56 (2006.01)
C07D 401/04 (2006.01)
C07D 401/12 (2006.01)
C07D 401/14 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.11.23
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.07.15
(86)	European Application Nr.	14848083.3
(86)	European Filing Date	2014.09.29
(87)	The European Application's Publication Date	2016.08.10
(30)	Priority	2013.10.16, CN, 201310485048 2013.09.30, US, 201361884958 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Guangzhou InnoCare Pharma Tech Co., Ltd., Room 899 No. 333 Jiufo Jianshe Road, Sino-Singapore Guangzhou Knowledge CityGuangzhouGuangdong 510130, Kina
(72)	Inventor	CHEN, Xiangyang, c/o Beijing InnoCare Pharma Tech Co., LtdBldg. 8, No. 8 Life Park RoadZGC Life Science Park, Changping DistrictBeijing 102206, Kina GAO, Yingxiang, c/o Beijing InnoCare Pharma Tech Co., LtdBldg. 8, No. 8 Life Park RoadZGC Life Science Park, Changping DistrictBeijing 102206, Kina LIU, Chong, No. 233 North Fu Te RoadWaigaoqiao Free Trade Zone, Shanghai 200131, Kina

NI, Haihong, No. 233 North Fu Te RoadWaigaoqiao Free Trade Zone, Shanghai
200131, Kina
MULVIHILL, Mark, X-Rx Discovery Inc.100 Beaver Street, Waltham, MA 02453,
USA

(74) Agent or Attorney CURO AS, Vestre Rosten 81, 7075 TILLER, Norge

(54) Title **SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE
IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE**

(56) References
Cited:


WO-A1-2014/082598
WO-A2-2012/170976
WO-A1-2008/033834
WO-A2-2007/117692
WO-A1-2009/158571
WO-A2-2006/099075
WO-A1-2014/068527

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>


Patentkrav

1. Forbindelse valgt fra gruppen bestående av:


6-(1-akryloylpiperidin-4-yl)-2-(4-fenoksyfenyl)nikotinamid;



6-(4-akryloylpiperazin-1-yl)-2-(4-fenoksyfenyl)nikotinamid;




6-(1-akryloylpyrrolidin-3-yl)-2-(4-fenoksyfenyl)nikotinamid;




10


6-(1-akryloylpiperidin-3-yl)-2-(4-fenoksyfenyl)nikotinamid;




(E)-6-(4-(dimethylamino)men-2-enoyl)piperazin-1-yl)-2-(4-fenoksyfenyl)nikotinamid;




6-(4-akryloylpiperazin-1-yl)-2-(4-(4-cyanofenoksy)fenyl)nikotinamid;



6-(4-akryloylpiperazin-1-yl)-2-(4-(3-fluorofenoksy)fenyl)nikotinamid;




6-(4-akryloylpiperazin-1-yl)-2-(3-fluor-4-fenoksyfenyl)nikotinamid;




5

6-(4-akryloylpiperazin-1-yl)-2-(4-(4-fluorofenoksy)fenyl)nikotinamid;




6-(4-akryloylpiperazin-1-yl)-2-(4-(2-fluorofenoksy)fenyl)nikotinamid;




10


6-(4-akryloylpiperazin-1-yl)-2-(2-fluor-4-fenoksyfenyl)nikotinamid;




5-(1-akryloylpiperidin-4-yl)-4'-fenoksybifenyl-2-karboksamid;




5-(4-akryloylpiperazin-1-yl)-4'-fenoksybifenyl-2-karboksamid;



5
2-(4-fenoksyfenyl)-6-(4-(vinylsulfonyl)piperazin-1-yl)nikotinamid;








2-(4-fenoksyfenyl)-6-(1-(vinylsulfonyl)piperidin-4-yl)nikotinamid;






eller et farmasøytisk akseptabelt salt av samme.

2. Forbindelse ifølge krav 1, som er



5





eller

- 5 3. Farmasøytisk blanding omfattende en forbindelse i samsvar med ett av kravene 1 eller krav 2, eller et farmasøytisk akseptabelt salt av samme.
4. Farmasøytisk blanding for anvendelse i behandling kreft, kronisk betennelse, eller en autoimmun sykdom hos et pattedyr, omfattende en forbindelse i samsvar med ett av kravene 1 eller krav 2, eller et farmasøytisk akseptabelt salt av samme.